Death of a clinical trial: a speculative inclusion criterion gone wrong.
Rosenthal
M A
MA
Woo
H
H
Gurney
H
H
Copeman
M
M
Zingarelli
G
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001315:Australia; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000627:therapeutic use; D000077143:Docetaxel; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic; D020133:Reverse Transcriptase Polymerase Chain Reaction; D043823:Taxoids / Q000627:therapeutic use; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; D000077143:Docetaxel; D000077211:Zoledronic Acid; D017430:Prostate-Specific Antigen